Heartmate XVE® destination therapy for end-stage heart failure in a patient with human immunodeficiency virus

Abstract

Cardiac dysfunction is a known predictor of survival in patients with acquired immunodeficiency syndrome. In this report, we describe a human immunodeficiency virus (HIV)-infected patient with worsening heart failure who was managed successfully for 16 months with placement of a left ventricular assist device.